Wheler, J. J., Tsimberidou, A. M., Falchook, G. S., Zinner, R. G., Hong, D. S., Fok, J. Y., . . . Kurzrock, R. (2013). Combining Erlotinib and Cetuximab is Associated with Activity in Patients with Non Small Cell Lung Cancer (including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations.
Čikaški stil citiranjaWheler, Jennifer J., et al. Combining Erlotinib and Cetuximab Is Associated With Activity in Patients With Non Small Cell Lung Cancer (including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations. 2013.
MLA način citiranjaWheler, Jennifer J., et al. Combining Erlotinib and Cetuximab Is Associated With Activity in Patients With Non Small Cell Lung Cancer (including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations. 2013.